BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.
Küçük Resim Yok
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Lippincott Williams & Wilkins
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
[Abstract Not Available]
Açıklama
Anahtar Kelimeler
Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Untreated Patients
Kaynak
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
41
Sayı
16
Künye
Sevindik, Ö. G., Chen, C., Yang, J., Farooqui, M. Z. H. ve Paszkiewicz-Kozik, E. (2023). BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL, 02-06 June, 2023.
